Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BHMT | Q93088 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3958660 | 1.00 | S1PR2 (0.46) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL2909702 | 1.00 | S1PR2 (0.46) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL584298 | 1.00 | S1PR2 (0.46) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL2909705 | 1.00 | S1PR2 (0.46) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 | |
| Hydrochloric Acid SCHEMBL1199813 | 0.98 | S1PR2 (0.45) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 | |
| Hydrochloric Acid SCHEMBL3140001 | 0.98 | S1PR2 (0.45) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL3967142 | 0.95 | GPR84 (0.50) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL3963429 | 0.95 | GPR84 (0.50) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 | |
| Imagabalin SCHEMBL119441 | 0.89 | ALDH1A1 (0.43) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 | |
| Imagabalin SCHEMBL3961605 | 0.89 | ALDH1A1 (0.43) | S1PR2S1PR1SLC1A2SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 872 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2022-11-03 | — | — | US | claimed |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2022-10-18 | — | — | US | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| US-20140206670-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER INC. (US) | 2014-07-24 | — | — | US | claimed |
| US-20120329781-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER INC | 2012-12-27 | — | — | US | claimed |
| EP-2125021-B8 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH ALPHA 2DELTA LIGANDS AND NSAIDS | RECORDATI IRELAND LTD (IE) | 2012-02-15 | — | — | EP | claimed |
| EP-2125021-B1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH 2 LIGANDS AND NSAIDS | RECORDATI IRELAND LTD (IE) | 2011-06-08 | — | — | EP | claimed |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-20110039875-A1 | PHARAMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY | TRINITY LABORATORIES, INC. | 2011-02-17 | — | — | US | claimed |
| WO-2005002585-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | claimed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | claimed |
| US-20040157847-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-08-12 | — | — | US | claimed |
| US-20040143014-A1 | Therapeutic use of alpha-2-delta ligands | PFIZER INC | 2004-07-22 | — | — | US | claimed |
| WO-2004054577-A1 | ALPHA-2-DELTA LIGANDS TO TREAT OCD AND RELATED DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040092522-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-05-13 | — | — | US | claimed |
| WO-2004016259-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | claimed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | S1PR2 580/4885S1PR1 843/4885SLC1A2 1631/4885 |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | CRH, HTR5A, NPY5R | S1PR2 3188/4885S1PR1 3065/4885SLC1A2 228/4885 |
| US-20040092522-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | S1PR2 593/4885S1PR1 1254/4885SLC1A2 788/4885 |
| US-20040143014-A1 | Therapeutic use of alpha-2-delta ligands | CHRND, CHRNG, CHRNE | S1PR2 277/4885S1PR1 442/4885SLC1A2 2302/4885 |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | S1PR2 3188/4885S1PR1 3065/4885SLC1A2 228/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | S1PR2 3395/4885S1PR1 4348/4885SLC1A2 19/4885 |
| US-20120329781-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | SLC6A2, OPRD1, ADRB2 | S1PR2 54/4885S1PR1 88/4885SLC1A2 78/4885 |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | S1PR2 3188/4885S1PR1 3065/4885SLC1A2 228/4885 |
| US-20140206670-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | SLC6A2, OPRD1, ADRB2 | S1PR2 54/4885S1PR1 88/4885SLC1A2 78/4885 |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, CHRNG | S1PR2 102/4885S1PR1 352/4885SLC1A2 1873/4885 |
| US-20040157847-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | S1PR2 593/4885S1PR1 1254/4885SLC1A2 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.